127 related articles for article (PubMed ID: 34678602)
1. Structure-activity relationship and biological evaluation of 12 N-substituted aloperine derivatives as PD-L1 down-regulatory agents through proteasome pathway.
Zeng QX; Wang K; Zhang X; Shi YL; Dou YY; Guo ZH; Zhang XT; Zhang N; Deng HB; Li YH; Song DQ
Bioorg Chem; 2021 Dec; 117():105432. PubMed ID: 34678602
[TBL] [Abstract][Full Text] [Related]
2. Molecular hybridization used to design and synthesize neo-tanshinlactone derivatives as PD-1/PD-L1 inhibitors.
Zhang M; Liu J; Wang Y; Wang P; Morris-Natschke S; Lee KH
Bioorg Med Chem; 2022 Jan; 54():116579. PubMed ID: 34954618
[TBL] [Abstract][Full Text] [Related]
3. Improving tumor sensitivity by the introduction of an ester chain to triaryl derivatives targeting PD-1/PD-L1.
Zhang Y; Yin F; Luo Z; Li S; Li X; Wan S; Chen Y; Kong L; Wang X
Eur J Med Chem; 2024 May; 271():116433. PubMed ID: 38678826
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and structure-activity relationship of programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing a benzo[d]isothiazole scaffold.
Chen H; Wang K; Yang Y; Huang X; Dai X; Feng Z
Eur J Med Chem; 2021 May; 217():113377. PubMed ID: 33770574
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel quinazoline derivatives as immune checkpoint inhibitors.
Thuy Lu Vo T; Hoang VH; Thi Phuong Dung P; Anh Chi N; Minh Huy V; Tung Ngo S; Thi Kim Nguyen Y; Thi Thu Hien T; Hoang TH; Thi Do Y; Hae Seo J; Tran PT
Bioorg Med Chem Lett; 2024 Aug; 108():129796. PubMed ID: 38754563
[TBL] [Abstract][Full Text] [Related]
6. Anticancer Activities of Hesperidin via Suppression of Up-Regulated Programmed Death-Ligand 1 Expression in Oral Cancer Cells.
Wudtiwai B; Makeudom A; Krisanaprakornkit S; Pothacharoen P; Kongtawelert P
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500779
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel CA-4 analogs as dual inhibitors of tubulin polymerization and PD-1/PD-L1 interaction for cancer treatment.
Yang X; Cheng B; Xiao Y; Xue M; Liu T; Cao H; Chen J
Eur J Med Chem; 2021 Mar; 213():113058. PubMed ID: 33280898
[TBL] [Abstract][Full Text] [Related]
8. Metformin Liposome-Mediated PD-L1 Downregulation for Amplifying the Photodynamic Immunotherapy Efficacy.
Xiong W; Qi L; Jiang N; Zhao Q; Chen L; Jiang X; Li Y; Zhou Z; Shen J
ACS Appl Mater Interfaces; 2021 Feb; 13(7):8026-8041. PubMed ID: 33577301
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and structure-activity relationship of PD-1/PD-L1 inhibitors with a benzo[d]isoxazole scaffold.
Huang X; Chen H; Dai X; Xu M; Wang K; Feng Z
Bioorg Med Chem Lett; 2021 Nov; 52():128403. PubMed ID: 34610423
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1.
Cheng B; Ren Y; Cao H; Chen J
Eur J Med Chem; 2020 Aug; 199():112377. PubMed ID: 32388281
[TBL] [Abstract][Full Text] [Related]
12. SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1.
Zhang N; Dou Y; Liu L; Zhang X; Liu X; Zeng Q; Liu Y; Yin M; Liu X; Deng H; Song D
EBioMedicine; 2019 Feb; 40():151-162. PubMed ID: 30711516
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Small and Bifunctional Molecules Targeting PD-L1/CD73 for Cancer Dual Immunotherapy.
Wang S; Kong Z; Shi Y; Shao C; Wang W; Su Z; Liu J; Zhou Y; Fei X; Cheng B; Chen J; Lu Y; Xiao J
J Med Chem; 2024 Jun; 67(11):9447-9464. PubMed ID: 38748913
[TBL] [Abstract][Full Text] [Related]
14. Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect.
Gao T; Mao Z; Li W; Pei R
J Mater Chem B; 2021 Jan; 9(3):746-756. PubMed ID: 33319876
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
Yang Y; Wang K; Chen H; Feng Z
Eur J Med Chem; 2021 Feb; 211():113001. PubMed ID: 33272783
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy.
Wang F; Ye W; Wang S; He Y; Zhong H; Wang Y; Zhu Y; Han J; Bing Z; Ji S; Liu H; Yao X
Neoplasia; 2021 Mar; 23(3):281-293. PubMed ID: 33529880
[TBL] [Abstract][Full Text] [Related]
17. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 4-phenyl-1H-indazole derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction.
Xu C; Sun Z; Zhang X; Zang Q; Yang Z; Li L; Yang X; He Y; Ma Z; Chen J
Bioorg Chem; 2024 Jun; 147():107376. PubMed ID: 38640722
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC).
Wang Y; Zhou Y; Cao S; Sun Y; Dong Z; Li C; Wang H; Yao Y; Yu H; Song X; Li M; Wang J; Wei M; Yang G; Yang C
Bioorg Chem; 2021 Jun; 111():104833. PubMed ID: 33839580
[TBL] [Abstract][Full Text] [Related]
20. Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[
Liu L; Yao Z; Wang S; Xie T; Wu G; Zhang H; Zhang P; Wu Y; Yuan H; Sun H
J Med Chem; 2021 Jun; 64(12):8391-8409. PubMed ID: 34115499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
